Share chart PepGen Inc.
About
PepGen Inc., биотехнологическая компания клинической стадии, занимается разработкой олигонуклеотидных терапевтических средств для лечения тяжелых нервно-мышечных и неврологических заболеваний. Ведущим продуктом компании-кандидата является PGN-EDO51, пептид EDO, проходящий фазу I клинических испытаний для лечения пациентов с мышечной дистрофией Дюшенна (МДД). Он также разрабатывает PGN-EDODM1, конъюгированный с пептидом EDO PMO для лечения миотонической дистрофии 1 типа, а также терапевтические кандидаты EDO, такие как PGN-EDO53, PGN-EDO45 и PGN-EDO44 для лечения МДД.
More detailsЦена ао | 8.33 |
---|---|
Сайт | https://www.pepgen.com |
EV/EBITDA | 2.8 |
EBITDA | -0.0012 |
P/BV | 1.92 |
ISIN | US7133171055 |
Число акций ао | 0.0238 млрд |
Валюта | usd |
IPO date | 2022-05-06 |
Sector | Health Care |
Industry | Biotechnology |
Валюта отчета | usd |
Change price per day: | 0% (8.81) |
---|---|
Change price per week: | -5.88% (9.36) |
Change price per month: | -7.07% (9.48) |
Change price per 3 month: | -51.06% (18) |
Change price per half year: | -23.39% (11.5) |
Change price per year: | +62.55% (5.42) |
Change price per year to date: | +89.06% (4.66) |
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
Institutions | Volume | Share, % |
---|---|---|
RA Capital Management, L.P. | 8131952 | 25.13 |
Viking Global Investors, L.P. | 1482434 | 4.58 |
Adage Capital Partners GP L.L.C. | 1100000 | 3.4 |
Janus Henderson Group PLC | 988204 | 3.05 |
FMR, LLC | 738022 | 2.28 |
Blackrock Inc. | 723538 | 2.24 |
Laurion Capital Management, LP | 664516 | 2.05 |
Vanguard Group Inc | 506179 | 1.56 |
Suvretta Capital Management, LLC | 486611 | 1.5 |
Samsara BioCapital, LLC | 436813 | 1.35 |
ETF | Share, % | Profitability for 1 year, % | Dividends, % |
---|---|---|---|
Avantis U.S Small Cap Equity ETF | 0.01592 | 27.774101036841 | 1.68271 |
Avantis U.S. Equity ETF | 0.00018 | 30.365392144069 | 1.59151 |
Dimensional U.S. Core Equity 2 ETF | 0.00004 | 30.755198832543 | 1.47098 |
Dimensional U.S. Targeted Value ETF | 0.00017 | 26.007247921552 | 1.93487 |
Dimensional US Core Equity Market ETF | 0.00037 | 30.983243755928 | 1.40618 |
Dimensional U.S. Equity ETF | 0.00013 | 31.530984204131 | 1.3557 |
Invesco Dorsey Wright SmallCap Momentum ETF | 0.20834 | 33.912466843501 | 0.61241 |
ProShares Hedge Replication ETF | 0.00088 | 5.9237999659878 | 1.47892 |
iShares Neuroscience and Healthcare ETF | 0.44149 | 19.720292847757 | 0.03 |
iShares Micro-Cap ETF | 0.03667 | 34.327031588619 | 1.54048 |
iShares Russell 2000 Growth ETF | 0.0092 | 38.042556988 | 0.6026 |
iShares Russell 3000 ETF | 0.00046 | 31.230028873917 | 1.43482 |
ProShares UltraPro Russell2000 | 0.00309 | 89.821266282945 | 1.47873 |
Vanguard Russell 3000 ETF | 0 | 31.87314172448 | 1.43817 |
Vanguard Russell 2000 Growth ETF | 0.01 | 37.361289927043 | 0.60264 |
Vanguard Russell 2000 ETF | 0.01 | 32.773459189339 | 1.48801 |
Head | Job title | Payment | Year of birth |
---|---|---|---|
Dr. James G. McArthur Ph.D. | President, CEO, Treasurer, Secretary & Director | 834.98k | 1962 (62 years) |
Dr. Michelle L. Mellion M.D. | Chief Medical Officer | N/A | 1976 (48 years) |
Mr. Niels Svenstrup Ph.D. | Senior Vice President of Chemistry, Manufacturing & Control | 455.15k | 1970 (54 years) |
Mr. Noel P. Donnelly M.B.A. | Chief Financial Officer | 650.17k | 1970 (54 years) |
Dr. Michael Gait Ph.D. | Founder & Scientific Advisory Board Member | N/A | |
Ms. Emiko Bryant | Chief of Staff | N/A | |
Mr. David E. Borah C.F.A. | Senior VP of IR & Corporate Communications | ||
Ms. Mary Beth DeLena J.D. | General Counsel & Secretary | 1968 (56 years) | |
Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs | ||
Dr. Afsaneh Mohebbi Ph.D. | Senior VP of Portfolio and Program Management |
Website: https://www.pepgen.com